<p>This is a summary of the European public assessment report (EPAR) for Cervarix. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cervarix.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types. See sections 4.4 and 5.1 for important information on the data that support this indication.</p> <p>The use of Cervarix should be in accordance with official recommendations.</p></div>
Therapeutic Area (MeSH)
ATC Code
J07BM02
ATC Item
N/A
Pharmacotherapeutic Group
Vaccines
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| human papillomavirus1 type 16 L1 protein | N/A | human papillomavirus1 type 16 L1 protein |
| human papillomavirus type 18 L1 protein | N/A | human papillomavirus type 18 L1 protein |
EMA Name
Cervarix
Medicine Name
Cervarix
Aliases
N/ANo risk management plan link.
